The total number of records retrieved from this search are 58. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
OV_68	Adenovirus	Ad5WS1	DNA	Adenoviridae	E1B55K-deleted mutant driven by the E1 promoter	Yes	No	No	NA	Human breast cancer line	MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	NA	NA	Crystal violet staining	0.001 MOI	100% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	26515462
OV_69	Adenovirus	Ad5WS1	DNA	Adenoviridae	E1B55K-deleted mutant driven by the E1 promoter	Yes	No	No	NA	Human breast cancer line	MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	NA	NA	Crystal violet staining	0.01 MOI	100% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	26515462
OV_70	Adenovirus	Ad5WS1	DNA	Adenoviridae	E1B55K-deleted mutant driven by the E1 promoter	Yes	No	No	NA	Human breast cancer line	MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	NA	NA	Crystal violet staining	0.1 MOI	96% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	26515462
OV_71	Adenovirus	Ad5WS1	DNA	Adenoviridae	E1B55K-deleted mutant driven by the E1 promoter	Yes	No	No	NA	Human breast cancer line	MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	NA	NA	Crystal violet staining	1 MOI	80% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	26515462
OV_72	Adenovirus	Ad5WS1	DNA	Adenoviridae	E1B55K-deleted mutant driven by the E1 promoter	Yes	No	No	NA	Human breast cancer line	MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	NA	NA	Crystal violet staining	10 MOI	20% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	26515462
OV_77	Adenovirus	AdLacZ	DNA	Adenoviridae	E1/E3-deleted mutant	Yes	No	No	NA	Human breast cancer line	MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	NA	NA	Crystal violet staining	0.01 MOI	100% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	26515462
OV_78	Adenovirus	AdLacZ	DNA	Adenoviridae	E1/E3-deleted mutant	Yes	No	No	NA	Human breast cancer line	MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	NA	NA	Crystal violet staining	0.1 MOI	100% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	26515462
OV_79	Adenovirus	AdLacZ	DNA	Adenoviridae	E1/E3-deleted mutant	Yes	No	No	NA	Human breast cancer line	MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	NA	NA	Crystal violet staining	1 MOI	100% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	26515462
OV_80	Adenovirus	AdLacZ	DNA	Adenoviridae	E1/E3-deleted mutant	Yes	No	No	NA	Human breast cancer line	MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	NA	NA	Crystal violet staining	10 MOI	100% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	26515462
OV_90	Adenovirus	Ad5GS3	DNA	Adenoviridae	E1B55K-deleted mutant driven by the MDR1 promoter	Yes	No	No	NA	Human breast cancer line	MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	NA	NA	Crystal violet staining	0.001 MOI	100% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	26515462
OV_91	Adenovirus	Ad5GS3	DNA	Adenoviridae	E1B55K-deleted mutant driven by the MDR1 promoter	Yes	No	No	NA	Human breast cancer line	MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	NA	NA	Crystal violet staining	0.01 MOI	100% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	26515462
OV_92	Adenovirus	Ad5GS3	DNA	Adenoviridae	E1B55K-deleted mutant driven by the MDR1 promoter	Yes	No	No	NA	Human breast cancer line	MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	NA	NA	Crystal violet staining	0.1 MOI	94% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	26515462
OV_93	Adenovirus	Ad5GS3	DNA	Adenoviridae	E1B55K-deleted mutant driven by the MDR1 promoter	Yes	No	No	NA	Human breast cancer line	MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	NA	NA	Crystal violet staining	1 MOI	75% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	26515462
OV_94	Adenovirus	Ad5GS3	DNA	Adenoviridae	E1B55K-deleted mutant driven by the MDR1 promoter	Yes	No	No	NA	Human breast cancer line	MCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation)	NA	NA	Crystal violet staining	10 MOI	16% cancer cell viability	No	No	NA	No response	NA	NA	NA	NA	26515462
OV_487	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	102% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_488	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	108% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_491	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	98% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_492	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	102% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_495	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	96% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_496	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	100% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_499	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	80% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_500	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	37% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_503	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	56% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_504	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	12% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_507	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	99% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_508	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	92% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_511	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	84% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_512	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	73% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_515	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	65% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_516	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_519	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_520	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_523	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	36% cancer cell viability (calculated as relative to mock-infected group), antagonist effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_524	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	10% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_527	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	83% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_528	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	79% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_531	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	77% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_532	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	69% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_535	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	60% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_536	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_539	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	45% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_540	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_543	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	35% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_544	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	12% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_547	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	65% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_548	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	50% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_551	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	60% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_552	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	44% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_555	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_556	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_559	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	38% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_560	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	22% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_563	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	25% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_564	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	10% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	NA	NA	NA	27356624
OV_2875	Vaccinia virus	vvDD	DNA	Poxviridae	Deletion of TK gene and vaccinia growth factor	Yes	No	No	Laboratory grown own culture	Osteosarcoma cell line	HOS	5.0E+3 cells per well	NA	MTT assay	0.01 MOI	30% cell survival	No	No	NA	No response	NA	NA	NA	NA	23816608
OV_2876	Vaccinia virus	vvDD	DNA	Poxviridae	Deletion of TK gene and vaccinia growth factor	Yes	No	No	Laboratory grown own culture	Osteosarcoma cell line	HOS	5.0E+3 cells per well	NA	MTT assay	0.1 MOI	20% cell survival	No	No	NA	No response	NA	NA	NA	NA	23816608
OV_2877	Vaccinia virus	vvDD	DNA	Poxviridae	Deletion of TK gene and vaccinia growth factor	Yes	No	No	Laboratory grown own culture	Osteosarcoma cell line	HOS	5.0E+3 cells per well	NA	MTT assay	1 MOI	10% cell survival	No	No	NA	No response	NA	NA	NA	NA	23816608
OV_2878	Vaccinia virus	vvDD	DNA	Poxviridae	Deletion of TK gene and vaccinia growth factor	Yes	No	No	Laboratory grown own culture	Osteosarcoma cell line	HOS	5.0E+3 cells per well	NA	MTT assay	10 MOI	5% cell survival	No	No	NA	No response	NA	NA	NA	NA	23816608